Background: Several extrathoracic tumors metastasize to the mediastinum. Mediastinoscopy is the standard method to obtain tissue proof of mediastinal spread, but drawbacks are its invasiveness, requirement for general anesthesia and costs. Transesophageal endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is indicated in lung cancer staging guidelines as a minimally invasive alternative for surgical staging. The diagnostic values in patients with suspected mediastinal metastases and various (previous) extrathoracic malignancies were assessed.
introduction
Several frequently diagnosed extrathoracic malignancies (e.g. breast cancer, renal cell carcinoma) can metastasize to the mediastinum in up to 30% of the cases [1, 2] . Tissue proof of presumed mediastinal spread is mandatory for an accurate diagnosis and staging as well as treatment planning. Obtaining a tissue diagnosis from mediastinal lymph nodes is often challenging due to their centrally located position in the chest. Imaging modalities such as computed tomography (CT), positron emission tomography (PET) and invasive tissue sampling techniques (e.g. mediastinoscopy) are currently available for mediastinal staging. CT and PET provide information regarding size and metabolic activity, respectively, but do not provide a tissue diagnosis. Enlarged and PETpositive nodes require tissue verification to make an accurate assessment of presumed tumor recurrence or mediastinal spread. Mediastinoscopy is the standard method for mediastinal lymph node staging [3] . Although an established method, drawbacks are its invasiveness, requirement for general anesthesia, clinical admission and costs.
Transesophageal endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is a minimally invasive outpatient procedure by which mediastinal lymph nodes can be aspirated under real-time ultrasound guidance. In a systematic review, EUS-FNA has a pooled sensitivity of 83% [95% confidence interval (CI) 78% to 87%] and a pooled specificity of 97% (95% CI 96% to 98%) for staging in patients with non-smallcell lung cancer [4] . Endoscopic ultrasound (EUS) is more sensitive (88% versus 57%) and specific (91% versus 82%) than CT [5] , more specific (100% versus 72%) than PET and just as accurate (93% versus 90%) as mediastinoscopy [6] . EUS-FNA prevents 50%-70% of scheduled surgical interventions in patients with (suspected) lung cancer and enlarged mediastinal lymph nodes [7, 8] . Therefore, EUS is indicated as a minimally invasive alternative for surgical staging in recent lung cancer staging guidelines [3] . Previous case series indicated that EUS-FNA might also be useful to provide tissue proof of mediastinal spread in patients with a current or previous extrathoracic original article * Table 1 .
EUS-FNA
EUS-FNA investigations were carried out at the Departments of Pulmonary Medicine of the Leiden University Medical Center (n = 46) and Radboud University Medical Center (n = 29). EUS-FNA examinations were carried out in a standardized way on an outpatient basis under conscious sedation using midazolam with a linear scanning Pentax FG 34 UX or EG 3870 UTK echoendoscope in combination with a Hitachi EUB 6500 ultrasound scanner. Sonographically suspected lymph nodes (round shape, sharp borders, short axis >10 mm, hypoechoic echo texture) were aspirated under realtime ultrasound guidance from the esophagus with a 22-gauge needle (GIP/ Medi-Globe GmbH, Achenmühle, Germany; type Hancke/Vilmann or Medi-Globe type Sonotip II, GUS-01-27-022) (Figure 1 ). The aspirated material was stained and examined on site for adequacy, before assessment by an experienced cytopathologist. Conventional smears were always available, and when sufficient aspirate was available, cell blocks were made on which immunohistochemistry analysis was carried out (Figure 1 ).
data analysis
The primary end point of the study was the determination of the diagnostic yield of EUS-FNA in patients with suspected mediastinal metastases and an (previous) extrathoracic malignancy. EUS aspirates showing malignancy were regarded as true positives. Tumor-positive EUS findings were not surgically validated as it was judged unethical to do so. The reference standard in patients in whom EUS did not establish metastasis was surgical staging of the mediastinum or clinical and radiological follow-up. Statistical analysis was carried out with the Statistical Package for the Social Sciences (SPSS) 12.
results
It was feasible to carry out a standardized EUS-FNA investigation in all patients. The mean size of the mediastinal lymph nodes detected by EUS was 15 mm (range 5-50 mm). Nodes were aspirated on average three times (range 0-7). Most EUS-guided aspirations (n = 45, 60%) were from the subcarinal , n = 7 (9%) ( Table 2) ]. Recurrent metastatic disease in patients with a previous extrathoracic malignancy was diagnosed after a median disease-free interval of 3.5 years (range 3 months to 20 years). In seven patients (9%), an alternative diagnosis was established (Table 2 ). In 25 patients (33%), EUS aspirates showed either reactive lymph node tissue (n = 16, 21%) or nonrepresentative material (n = 9, 12%) ( Table 2 ). Of these, seven patients underwent surgical staging of the mediastinum establishing mediastinal metastases in six and granulomatosis in one. One patient demonstrated progressive mediastinal disease radiologically without tissue proof and was considered tumor positive. In the remaining 17 patients, no mediastinal malignancy was detected during clinical and radiological median follow-up of 6 months (range 3-18 months). The final diagnosis of the mediastinum revealed metastases in 50 of the 75 patients (prevalence 66%). Sensitivity, specificity, accuracy and NPV of EUS-FNA for the detection of mediastinal malignancy were 86%, 100%, 91% and 72%, respectively. One complication of mediastinitis occurred following EUS-FNA of a bronchogenic cyst as previously reported [13] .
discussion
In patients with an (previous) extrathoracic malignancy and suspected mediastinal metastases, EUS-FNA demonstrated a high sensitivity (86%) and accuracy (91%). The results of this study confirm findings of previous smaller reports. In a study involving 20 patients with a history of extrathoracic malignancy and mediastinal abnormality, EUS had a sensitivity and accuracy of 69% and 75%, respectively [9] . In a case series in 12 patients with breast cancer, EUS had a 91% sensitivity regarding mediastinal staging [10] . In 17 patients with head and neck cancer and enlarged mediastinal lymph nodes, EUS findings of mediastinal metastases resulted in change of management in 47% patients [11] . The value of EUS-FNA in assessing mediastinal tumor spread of extrathoracic malignancies is similar to the mediastinal nodal staging in patients with lung cancer [4] . EUS-FNA of solid lesions is a safe procedure as only few complications are described such as mediastinitis following aspiration of a necrotic node [12] . Additionally, mediastinal cysts should not be aspirated due to the risk of infection [13] . So far, there is very little evidence for tumor spread into the esophagus or the stomach wall [14] . Due to its minimally invasive nature, EUS-FNA or endobronchial ultrasound (EBUS)-guided TBNA may be considered the initial tissue sample test to establish a tissue diagnosis in patients with suspected mediastinal involvement. Real-time ultrasound-guided nodal aspiration by EUS or EBUS has a higher sensitivity for mediastinal metastases in comparison to 'blind' conventional TBNA, which has a sensitivity between 39% and 78% depending on the prevalence of mediastinal disease [15] .
Cost-minimization models for the assessment of mediastinal nodal metastases demonstrate that the pretest probability of nodal metastases determines the most cost-effective strategy. EUS alone or combined with EBUS is less costly compared with conventional bronchoscopy or surgical staging [16] . In a staging strategy using PET, EUS-FNA reduced staging costs by 40% by preventing surgical staging [17] .
Due to the limited NPV (72%), tumor-negative findings should be verified by surgical techniques (e.g. mediastinoscopy). In our series, the false-negative cases were mainly due to sampling error. The limited number of needle passes (<3) may account for this. We conclude that EUS-FNA is an accurate and minimally invasive mediastinal staging procedure for patients with extrathoracic malignancies, and therefore it may qualify as an alternative for surgical staging.
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